STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.
DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
- Amy Rothberg, MD is a member of the Board of Directors for the American Board of Obesity Medicine, and is a member of the Finance Committee for the Obesity Society.
- Jaime Almandoz, MD: Novo Nordisk, Advisory Board/Consulting; Eli Lilly, Advisory Board/Consulting; Boehringer Ingelheim, Independent Contractor
- Jamy Ard, MD: Nestle Healthcare Nutrition, Consultant, Research support, Eli Lilly, Consultant, Research funding, Boehringer Ingelheim, Consultant, Research funding, Epitomee Inc, Research funding, UnitedHealth Group R&D, Consultant, Research funding, Intuitive, Consultant, Regeneron, Consultant, Novo Nordisk, Advisory board, Consultant,
- Jonathan Purnell, MD: Novo Nordisk, Advisor Global Obesity Program; Luciole Pharmaceuticals, Scientific Advisor
- Domenica Rubino, MD: Novo Nordisk, Investigator (Institutional), Speaker, Consultant/Scientific Advisor, writing support; Boehringer Ingelheim, Investigator (Institutional), Consultant, advisor; Epitomee Medical, Investigator (Institutional); Astra Zeneca, Investigator (Institutional); Eli Lilly, consultant; Prime Therapeutics, speaker; Medscape/WebMD, speaker
- Amanda Velazquez, MD: Weight Watchers, Advisory Board; Novo Nordisk, Consultant; Intellihealth, Advisory Board
The following faculty reported no relevant financial relationships: Michael Weintraub, MD
The following committee member who reviewed content for this activity reported relevant financial relationships: Dimpi Desai, MD
The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.
The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by educational grants from Lilly and Novo Nordisk.